Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimodulin in Hospitalized CAP or COVID-19 Pneumonia
NCT05531149Phase 3Terminated
- Sponsor
- Biotest AG
- Start
- Dec 2022
- Primary completion
- May 2025
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 14
01
Overview
A Phase 3 trial of Pentaglobin in community acquired pneumonia (CAP), COVID-19 pneumonia, sponsored by Biotest AG. Started Dec 2022; status: terminated.
02
Drugs
Pentaglobin
03
Conditions
community acquired pneumonia (CAP)COVID-19 pneumonia
Beyond the preview
Go deeper on NCT05531149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05531149.